Compare American Financial Group Inc (AFG) vs Biogen Inc (BIIB) Price & Performance

American Financial Group (AFG) trades at $144.82, up 0.66% today, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong Q2 2026 earnings of $2.82 per share, beating estimates, driven by property and casualty underwriting and investment income. Revenue for 2025 was $8.12 billion with a net income margin of 10.37%, while 2026 is projected at $8.2 billion with an 11.66% margin. Analysts have a consensus price target of $160.67, with 41% recommending buy.

AFG presents a positive outlook with solid earnings beats and a shareholder-friendly dividend policy, but faces risks from competitive pressures and potential market volatility. The stock's current valuation at a P/E of 12.62 offers room for growth relative to historical averages, supported by institutional interest and consistent cash flow generation.

Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.

Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.